Abstract
PCN83 Cost Effectiveness Analysis in the Veneto Region of Cabazitaxel Versus Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer, Previously Treated With a Docetaxel Containing Regimen
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have